The U.S. Food and Drug Administration (FDA) approved the first treatment for children suffering from rare vasculitis or inflammation of the blood vessels. According to the FDA, Genentech received the approval for Rituxan (rituximab) injection in combination with glucocorticoids (steroid hormones) to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older. Granulomatosis with polyangiitis (GPA) formerly known as Wegener’s granulomatosis is a rare disease that causes inflammation of the blood vessels in the nose, sinuses, throat, lungs and kidneys. Microscopic polyangiitis (MPA)…
Read MoreFDA approves first treatment for children with rare blood vessel diseases
